-
1.发明授权METHODS OF ADMINISTERING TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASURING 有权方法管理四氢生物蝶呤，相关组合物及测量方法的
公开(公告)号：EP2139485B1
公开(公告)日：2012-10-17
申请号：EP08745614.1
申请日：2008-04-11
发明人： OPPENHEIMER, Daniel, I. , DORENBAUM, Alejandro , OKHAMAFE, Augustus , FOEHR, Erik , CASTILLO, Sianna , KOSTEL, Paul, John
IPC分类号： A61K31/519 , A61K45/06 , A61P3/02 , A61P3/00 , A61P25/16
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/0053 , A61K9/0065 , A61K9/0095 , A61K9/08 , A61K9/1652 , A61K9/2027 , A61K9/2054 , A61K9/2086 , A61K9/4808 , A61K9/4858 , A61K9/4891 , A61K45/06 , C07B63/00 , C07D487/04 , G01N27/62 , G01N30/7233 , G01N33/6848 , H01J49/004 , Y10T436/147777 , A61K2300/00
-
2.发明公开METHODS OF ADMINISTERING TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASURING 有权方法管理四氢生物蝶呤，相关组合物及测量方法的
公开(公告)号：EP2139485A2
公开(公告)日：2010-01-06
申请号：EP08745614.1
申请日：2008-04-11
发明人： OPPENHEIMER, Daniel, I. , DORENBAUM, Alejandro , OKHAMAFE, Augustus , FOEHR, Erik , CASTILLO, Sianna , KOSTEL, Paul, John
IPC分类号： A61K31/519 , A61K45/06 , A61P3/02 , A61P3/00 , A61P25/16
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/0053 , A61K9/0065 , A61K9/0095 , A61K9/08 , A61K9/1652 , A61K9/2027 , A61K9/2054 , A61K9/2086 , A61K9/4808 , A61K9/4858 , A61K9/4891 , A61K45/06 , C07B63/00 , C07D487/04 , G01N27/62 , G01N30/7233 , G01N33/6848 , H01J49/004 , Y10T436/147777 , A61K2300/00
摘要： The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.
-
公开(公告)号：EP1965803A1
公开(公告)日：2008-09-10
申请号：EP06839043.4
申请日：2006-12-05
IPC分类号： A61K31/519 , A61P9/10 , A61P9/12
CPC分类号： A61K31/519 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to a novel methods and compositions for the therapeutic intervention of vascular complications associated with diabetes, hyperlipidemias, and various cardiovascular disorders including but not limited to recalcitrant hypertension, coronary artery disease, pulmonary arterial hypertension, congestive heart failure, and hemolytic anemias. More specifically, the specification describes methods and compositions for treating such vascular disorders using compositions comprising BH4 and derivative thereof. Combination therapies of BH4 and other therapeutic regimens are contemplated.
-
-
搜索结果
3 条记录 (耗时 0.014 秒)
